Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4173-4181

  Yin, Shuping ^a   Lockett, Jaron ^a   Meng, Yonghong ^a   Biliran Jr , Hector ^a   Blouse, Grant E ^a,b   Li, Xiaohua ^a   Reddy, Neelima ^a   Zhao, Zimin ^a   Lin, Xinli ^c   Anagli, John ^a,b   Cher, Michael L ^a   Sheng, Shijie ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c ProteomTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM ION; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MASPIN; PLASMIN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CELL GROWTH; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG PROTEIN BINDING; ENZYME ACTIVATION; FOCAL ADHESION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REDUCTION KINETICS;

CELL ADHESION; CELL LINE, TUMOR; FOCAL ADHESIONS; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; PLASMIN; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SERPINS; TRANSFECTION; URINARY PLASMINOGEN ACTIVATOR;

EID: 33646271356     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3514     Document Type: Article

References (42)

1. Bartuski AJ, Kamachi Y, Schick C, Overhauser J, Silverman GA. Cytoplasmic antiproteinase 2 (PI8) and bomapin (PI10) map to the serpin cluster at 18q21.3. Genomics 1997;43:321-8.
2. Schneider SS, Schick C, Fish KE, et al. A serine proteinase inhibitor locus at 18q21.3 contains a tandem duplication of the human squamous cell carcinoma antigen gene. Proc Natl Acad Sci U S A 1995;92:3147-51.
3. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263:526-9.
4. Sheng S. The promise and challenge toward the clinical application of maspin in cancer. Front Biosci 2004;9:2733-45.
5. Seftor RK, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ. maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998;58:5681-5.
6. Cher ML, Biliran HR, Jr., Bhagat S, et al. Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A 2003;100:7847-52.
7. Biliran H, Jr., Sheng S. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Res 2001;61:8676-82.
8. Odero-Marah VA, Khalkhali-Ellis Z, Chunthapong J, et al. Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther 2003;2:398-403.
9. Sager R, Sheng S, Anisowicz A, et al. RNA genetics of breast cancer: maspin as paradigm. Cold Spring Harb Symp Quant Biol 1994;59:537-46.
10. Sheng S, Carey J, Seftor EA, Dias L, Hendrix MJ, Sager R. Maspin acts at the cell membrane to inhibit invasion and motility of mammary and prostatic cancer cells. Proc Natl Acad Sci U S A 1996;93:11669-74.
11. Sheng S, Pemberton PA, Sager R. Production, purification, and characterization of recombinant maspin proteins. J Biol Chem 1994;269:30988-93.
12. Shi HY, Zhang W, Liang R, et al. Modeling human breast cancer metastasis in mice: maspin as a paradigm. Histol Histopathol 2003;18:201-6.
13. Zhang M, Shi Y, Magit D, Furth PA, Sager R. Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice. Oncogene 2000;19:6053-8.
14. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med 2000;6:196-9.
15. Liu J, Yin S, Reddy N, Spencer C, Sheng S. Bax mediates the apoptosis-sensitizing effect of maspin. Cancer Res 2004;64:1703-11.
16. Jiang N, Meng Y, Zhang S, Mensah-Osman E, Sheng S. Maspin sensitizes breast carcinoma cells to induced apoptosis. Oncogene 2002;21:4089-98.
17. Yin S, Li X, Meng Y, et al. Tumor suppressive maspin regulates cell response to oxidative stress by direct interaction with glutathione S-transferase. J Biol Chem 2005;280:34985-96.
18. Bailey CM, Khalkhali-Ellis Z, Kondo S, et al. Maspin binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 2005;280:34210-7.
19. Zamir E, Geiger B. Molecular complexity and dynamics of cell-matrix adhesions. J Cell Sci 2001;114:3583-90.
20. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004;14:92-101.
21. McGowen R, Biliran H, Jr., Sager R, Sheng S. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. Cancer Res 2000;60:4771-8.
22. Sheng S. The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev 2001;20:287-96.
23. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
24. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM. Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 1991;27:897-900.
25. Salonen EM, Vaheri A, Pollanen J, et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;64:6339-43.
26. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;8:1225-31.
27. Olson ST, Bock PE, Kvassman J, et al. Role of the catalytic serine in the interactions of serine proteinases with protein inhibitors of the serpin family. Contribution of a covalent interaction to the binding energy of serpin-proteinase complexes. J Biol Chem 1995;270:30007-17.
28. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005;11:3889-96.
29. Bradford DS, Foster RR, Nossel HL. Coagulation alterations, hypoxemia, and fat embolism in fracture patients. J Trauma 1970;10:307-21.
30. Abraham S, Zhang W, Greenberg N, Zhang M. Maspin functions as tumor suppressor by increasing cell adhesion to extracellular matrix in prostate tumor cells. J Urol 2003;169:1157-61.
31. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003;3:362-74.
32. Bastholm L, Elling F, Brunner N, Nielsen MH. Immunoelectron microscopy of the receptor for urokinase plasminogen activator and cathepsin D in the human breast cancer cell line MDA-MB-231. APMIS 1994;102:279-86.
33. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003;160:781-91.
34. Behrendt N, List K, Andreasen PA, Dano K. The prourokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal proenzyme activation. Biochem J 2003;371:277-87.
35. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
36. Chapman HA, Wei Y. Protease crosstalk with integrins: the urokinase receptor paradigm. Thromb Haemost 2001;86:124-9.
37. Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2004;3:932-43.
38. 1 integrin maturation and transport to the cell surface. J Biol Chem 2004;279:10005-12.
39. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996;213:65-80.
40. Tsatas D, Baker MS, Rice GE. Tissue-specific expression of the relaxed conformation of plasminogen activator inhibitor-2 and low-density lipoprotein receptor-related protein in human term gestational tissues. J Histochem Cytochem 1997;45:1593-602.
41. Reinartz J, Schaefer B, Bechtel MJ, Kramer MD. Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 1996;223:91-101.
42. Kounnas MZ, Henkin J, Argraves WS, Strickland DK. Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor mediates cellular uptake of pro-urokinase. J Biol Chem 1993;268:21862-7.